Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV immunotherapeutic vaccines.

B S Peters1

  • 1Department of GU Medicine, GKT School of Medicine, St Thomas' Hospital, London, UK. barry@bpeters.demon.co.uk

Antiviral Chemistry & Chemotherapy
|January 6, 2001
PubMed
Summary

Developing an effective therapeutic vaccine for human immunodeficiency virus (HIV) remains a priority. Current antiretroviral therapies have limitations, driving research into novel immunotherapeutic strategies for HIV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing risk of Type 2 diabetes in HIV: a mixed-methods investigation of the STOP-Diabetes diet and physical activity intervention.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

Therapy for HIV: past, present, and future.

Advances in dental research·2011
Same author

Clinical markers of immunodeficiency and mechanism of immune reconstitution inflammatory syndrome and highly active antiretroviral therapy on HIV: workshop 3A.

Advances in dental research·2011
Same author

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.

International journal of clinical practice·2010
Same author

Putting protection first: vascular risk assessment in atypical populations.

International journal of clinical practice·2010
Same author

Disseminated gonococcal infection in a homosexual man diagnosed by nucleic acid amplification testing from a skin lesion swab.

Sexually transmitted infections·2008

Area of Science:

  • Immunology
  • Virology
  • Vaccinology

Background:

  • Current antiretroviral treatments for HIV infection improve patient quality of life but present challenges like toxicity, drug resistance, and high costs.
  • An effective immunotherapeutic vaccine for HIV could overcome these limitations, offering a significant advancement in patient care.
  • Existing vaccine approaches have not demonstrated sufficient efficacy in controlling HIV replication or restoring immune function for clinical use.

Purpose of the Study:

  • To review the current landscape of therapeutic HIV vaccine development, highlighting challenges and promising new strategies.
  • To evaluate the progress and limitations of various immunotherapeutic approaches, including whole killed virus, recombinant proteins, and viral vectors.
  • To discuss the potential of novel strategies like DNA vaccination and fusion inhibitors in combating HIV infection.

Main Methods:

  • Review of clinical trial data and preclinical research on various HIV vaccine candidates.
  • Analysis of immunogenic responses (e.g., T-cell responses, viral load, CD4 counts) to different vaccine strategies.
  • Exploration of emerging therapeutic avenues, including recombinant viral vectors and fusion inhibitors.

Main Results:

  • Remune, a gp120-depleted whole killed HIV-1 vaccine, has shown cytotoxic T lymphocyte responses but disappointing CD4 and viral load improvements; it is entering Phase III trials.
  • Recombinant envelope protein (rgp160) and core antigen (p24VLP) vaccines have failed to elicit a therapeutic response.
  • Newer strategies using recombinant canarypox (ALVAC 1452) and attenuated vaccinia virus (NYVAC) show preliminary promise in reducing HIV replication, requiring further confirmation.
  • DNA vaccination has shown promise in animal models but not yet in humans; fusion inhibitors like T-20 are also under development.

Conclusions:

  • Despite challenges, therapeutic HIV vaccine development remains a critical research area due to the limitations of current treatments.
  • While some candidates like Remune are progressing, significant hurdles in achieving robust immune responses and clinical efficacy persist.
  • Ongoing research into novel vaccine platforms and combination strategies, alongside non-vaccine approaches like fusion inhibitors, is essential for advancing HIV treatment.

Related Experiment Videos